"Results: In our study, 21 patients qualified for enrolment. These patients received a median of 6 treatments prior to Pluvicto. Among them, 8 (38.1%) demonstrated at least PSA50 and showed response post-treatment. Of these, 6 (75%) completed all six Pluvicto treatments, while 2 (25%) are currently undergoing treatment. Remarkably, 7 of the 8 responders (87.5%) achieved a PSA50 response after two Pluvicto doses, with all 8 (100%) reaching this marker by the third dose. Furthermore, 6 of these 8 patients (75%) exhibited a PSA90 response after the fourth dose, though 2 patients (25%) did not attain PSA90"
The above just so anyone wondering sees the context of 87.5%, it's 87.5% of 38.1%.
It'll be interesting to see how TLX591 performs in the ph3, I haven't followed them much lately but as far as I know aside from a small ph1 trial a year or so back, they haven't actually done any of their own trials so this 43 month survival is based on trials done by some other mob many moons ago?
CU6 Price at posting:
$6.06 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)